tradingkey.logo

Roche Q3 sales advance by forex-adj 9%, beating market view

ReutersOct 23, 2024 5:26 AM


By Ludwig Burger

FRANKFURT (Reuters) -Roche's third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.

Group sales of 15.14 billion Swiss francs ($17.46 billion) surpassed an analysts' consensus estimate of 14.9 billion francs, based on LSEG data.

The Swiss drugmaker reaffirmed on Wednesday it expects growth in 2024 adjusted earnings per share in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023.

($1 = 0.8671 Swiss francs)

(Reporting by Ludwig Burger, Editing by Rachel More)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI